MajorAntiplatelet agents (low dose) / NSAIDs (analgesic dose)×Direct thrombin inhibitor
Updated · Methodology
Mechanism
Dabigatran is a direct, competitive and reversible inhibitor of thrombin, the key clotting enzyme (dabigatran summary of product characteristics, SmPC, European Medicines Agency, EMA). Acetylsalicylic acid strongly and irreversibly inhibits platelet aggregation by blocking platelet cyclooxygenase, which platelets cannot make again (acetylsalicylic acid SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). According to the dabigatran SmPC, acetylsalicylic acid 81 mg or 325 mg given with dabigatran 150 mg twice daily may raise the risk of any bleeding from 12% to 18% and 24%, respectively (EMA). In the RE-LY study in atrial fibrillation, concomitant acetylsalicylic acid or clopidogrel roughly doubled the rate of major bleeding with both dabigatran and warfarin (EMA).
Symptoms
The risk of bleeding rises. It may be overt or hidden, occur in any tissue or organ and may be fatal (dabigatran summary of product characteristics, SmPC, European Medicines Agency, EMA). With long-term dabigatran, mucosal bleeding, such as gastrointestinal and genitourinary bleeding, was seen more often than with vitamin K antagonists (EMA). Bleeding complications may present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or unexplained shock (EMA). With acetylsalicylic acid, black stools, vomiting blood, a drop in blood pressure, cold sweat, abdominal pain and dizziness may signal bleeding, especially from the upper gastrointestinal tract (acetylsalicylic acid SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).
Management
The combination is not contraindicated, but whenever possible, avoid combining acetylsalicylic acid with anticoagulants, dabigatran included. If the combination is judged necessary, use it with caution and warn the patient about the signs of bleeding and tell them to stop treatment if these signs appear (acetylsalicylic acid summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Antiplatelets significantly increase the risk of major bleeding, so weigh benefit and risk carefully and give dabigatran only if the benefit outweighs the bleeding risk (dabigatran SmPC, European Medicines Agency, EMA). If the combination cannot be avoided, the acetylsalicylic acid SmPC calls for careful monitoring of the INR, the international normalised ratio (AEMPS). The dabigatran SmPC, however, says the INR is unreliable in patients on dabigatran and false-positive INR elevations have been reported, so do not perform INR tests. Diluted thrombin time, ecarin clotting time and activated partial thromboplastin time can give useful information, but interpret them with caution (EMA). In atrial fibrillation patients at higher bleeding risk, choose a daily dabigatran dose of 300 mg or 220 mg after an individual assessment of thromboembolic and bleeding risk (EMA). While the drugs are combined, watch closely for signs of bleeding or anaemia. If haemoglobin, haematocrit or blood pressure falls without explanation, look for a bleeding site. Stop dabigatran if clinically relevant bleeding occurs (EMA). The 2021 European Heart Rhythm Association practical guide (EHRA 2021) lists concomitant antiplatelets among bleeding risk factors that require caution.
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- EHRA: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (2021)– Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–1676, Tables 5–8 and Figure 6
- AEMPS: Ficha técnica: Ácido acetilsalicílico, Adiro 100 mg (nº registro 62825) (2026)– AEMPS, CIMA, nº registro 62825 (Adiro 100 mg comprimidos gastrorresistentes EFG), revisión 07/2026, secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Dabigatrán etexilato, Pradaxa 150 mg (EU/1/08/442), sección 4.5 (2026)– EMA, Pradaxa 150 mg cápsulas duras (Boehringer Ingelheim International, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 08442011, consultada 30.10.2026, sin fecha de revisión en CIMA, secciones 4.2, 4.3, 4.4 (tabla 4), 4.5 (tabla 8) y 4.8